Apimeds Pharmaceuticals US (APUS) Income Statement: Revenue & Earnings

Apimeds Pharmaceuticals US Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Apimeds Pharmaceuticals US, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Revenue & Gross Profit
Revenue	0.00	0.00	0.00	0.00
Cost of Revenue	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00
Operating Expenses
Research & Development	0.00	0.10	0.37	0.49
Selling, General & Administrative	1.28	0.65	0.27	0.53
Operating Expenses	1.28	0.75	0.64	1.02
Operating Income	-1.28	-0.75	-0.64	-1.02
Other Income/Expense
Interest Income	0.00	0.01	0.00	0.00
Interest Expense	0.12	0.04	0.03	0.01
Other Income/Expense	-0.11	0.00	0.00	0.00
Income
Income Before Tax	-1.39	-0.78	-0.67	-1.03
Income Tax Expense	0.00	0.00	0.00	0.00
Net Income	-1.39	-0.78	-0.67	-1.03
Net Income - Continuous Operations	-1.39	-0.78	-0.67	-1.03
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00
EBITDA	-1.27	-0.74	-0.64	-1.02
EBIT	-1.27	-0.74	-0.64	-1.02
Depreciation & Amortization	0.00	0.00	0.00	0.00
Earnings Per Share
Basic EPS	-	-	-	-
Diluted EPS	-	-	-	-
Basic Shares Outstanding	11.53	11.57	11.57	11.57
Diluted Shares Outstanding	12.69	11.57	11.57	11.57